Upstream Bio to Present Phase 2 Data on Verekitug in CRSwNP at EAACI 2026
Event summary
- Upstream Bio will present additional Phase 2 VIBRANT trial data on verekitug for CRSwNP in an oral session at EAACI 2026 on June 14, 2026.
- The presentation will feature a responder analysis examining clinically meaningful improvements in key disease measures.
- Verekitug is the only known TSLP receptor antagonist in clinical development.
- Upstream Bio has three ongoing Phase 2 trials for verekitug in CRSwNP, severe asthma, and COPD.
The big picture
Upstream Bio's presentation at EAACI 2026 highlights the growing interest in TSLP receptor antagonists for treating severe respiratory disorders. The company's focus on verekitug, the only known antagonist in clinical development, positions it at the forefront of a potential new therapeutic class. Success in these Phase 2 trials could validate the broader applicability of TSLP receptor inhibition across multiple inflammatory diseases.
What we're watching
- Clinical Efficacy
- How the responder analysis data will impact the perceived potential of verekitug in CRSwNP.
- Development Pipeline
- The pace at which Upstream Bio advances verekitug through Phase 2 trials in multiple respiratory diseases.
- Market Positioning
- Whether Upstream Bio can leverage verekitug's unique mechanism to differentiate itself in the competitive respiratory disease market.
Related topics